Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma

Trial Profile

A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Doxorubicin (Primary) ; Ifosfamide (Primary) ; Mesna (Primary) ; Olaratumab (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 31 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 12 Sep 2018 Planned End Date changed from 1 Nov 2019 to 8 Nov 2019.
    • 12 Sep 2018 Planned primary completion date changed from 1 Nov 2019 to 8 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top